{"nctId":"NCT00784784","briefTitle":"Zanamivir Versus Trivalent Split Virus Influenza Vaccine","startDateStruct":{"date":"2008-11"},"conditions":["Influenza"],"count":64,"armGroups":[{"label":"Influenza vaccine","type":"EXPERIMENTAL","interventionNames":["Biological: Fluviral"]},{"label":"Antiviral prophylaxis","type":"EXPERIMENTAL","interventionNames":["Drug: Zanamivir"]}],"interventions":[{"name":"Fluviral","otherNames":[]},{"name":"Zanamivir","otherNames":["Relenza"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 18-69 years old as of 01/Nov/2008\n* have an understanding of the study, agree to its provisions, and give written informed consent prior to study entry\n* available for follow-up during the study period\n* if a women of child-bearing years, must meet criteria to prevent pregnancy\n\nExclusion Criteria:\n\n* allergy to any component of influenza vaccine or zanamivir\n* previous serious adverse event associated with influenza vaccination\n* receipt of influenza vaccine between 01/Mar/2008 and start of study\n* previous adverse event associated with the use of antiviral medications\n* expecting to be unable to take zanamivir for more than 72 hours during study period\n* planning to spend more than 2 consecutive weeks outside Canada or more than 100 km from the study site during study period\n* pregnant, or planning to become pregnant, during study period\n* breastfeeding, or planning to breastfeed, a child under 12 months of age during study period\n* receipt of immunoglobulin within six months of study entry\n* immunocompromising condition or therapy that would be expected to reduce the efficacy of vaccination\n* plans to receive cytotoxic or radiation therapy during study period\n* history of cardiovascular or pulmonary disease that has required hospital admission within the past year\n* history of asthma or other chronic respiratory disease\n* participating in a trial that will result in the receipt of an investigational medication during the period that zanamivir may be taken (15/Nov/2008 to 30/Apr/2009)","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"69 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Number of Subjects Adhering to Long-term Zanamivir Prophylaxis","description":"Number of subjects taking 80% or more doses per week of zanamivir (10 mg once daily), as influenza prophylaxis, for 13 weeks or longer (as measured by weekly diary and dose counts at study visits).","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"34","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Laboratory Confirmed Influenza Infections","description":"Four-fold increase in antibody titer 2 weeks post injection and end of study or positive laboratory test for influenza during study (polymerase chain reaction \\[PCR\\] or culture)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":20},"commonTop":[]}}}